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Letters to the Editor
Memantine Augmentation in a Down’s Syndrome
Adolescent with Treatment-Resistant
Obsessive-Compulsive Disorder
Scott R. Pekrul, MD, and Kate D. Fitzgerald, MD
To The Editor:
Down’s syndrome (DS) is a chromosomal disorder that isthe most frequent cause of intellectual disability (mental retar-
dation [MR]). Psychiatric comorbidity is relatively common in the
Down’s population, and is estimated to range from 18% to 38%
(Prasher and Day 1995; Capone et al. 2006). Although little research
has been completed with obsessive-compulsive disorder (OCD) in DS
populations, it is estimated to occur in from 0.8% to 4.5% of patients
(Prasher and Day 1995; Capone et al. 2006). OCD is characterized
by intrusive thoughts, images, or urges (obsessions) with purposeful
mental or physical actions (compulsions) aimed at reducing anxiety
caused by the obsession. OCD in DS patients is postulated to present
more often with compulsive behaviors of ordering and tidiness, such
as rearranging personal belongs or opening/closing doors, cabinets,
blinds, and light switches (Prasher and Day 1995; Capone et al. 2006),
driven by ‘‘just right’’ obsessions (Charlot et al. 2002).
First-line pharmacological treatment for OCD in non-
developmentally disordered populations is a serotonin reuptake in-
hibitor (SSRI), which is effective in 40–60% of cases (Pediatric OCD
Treatment Study [POTS] Team 2004; Abudy et al. 2011). Various
strategies for treatment-resistant OCD include switching to another
SSRI, augmentation with antipsychotics, or the use of a serotonin
norepinephrine agent (Abudy et al. 2011). More recently, there is
emerging evidence that glutamatergic agents such as memantine are
effective in treatment-resistant OCD in both adult and pediatric OCD
patients (Pasquni and Bodni 2006; Aboujaoude, Barry, Gamel, 2009;
Hezel et al. 2009; Stewart et al. 2010). Given that memantine has
demonstrated effectiveness in treatment-resistant OCD in non-
developmentally disabled patients, it may be helpful in DS popula-
tions with OCD. Here, we report on a case using memantine in an
adolescent with DS and OCD.
Case Report
N was a 16-year-old Caucasian male with a history of DS and mild
MR who presented to a university-based child/adolescent psychiatry
clinic with his biological parents for evaluation of obsessive behav-
iors. N had had no prior psychiatric history until age 14 when he
developed ‘‘just right’’ rituals. His symptoms were characterized by
compulsively turning off lights; insisting that all doors needed to be
shut; as well as aligning books, pictures, boxes, and sunglasses so they
were ‘‘just so.’’ He also displayed hoarding behaviors such as keeping
water bottles, sunglasses, and boxes. If a family member closed a
door, turned on a light, or misarranged his items, he became very
upset and agitated. He would engage in these behaviors up to 8 hours
per day, causing significant distress in the home.
N was evaluated by a community psychiatrist who diagnosed
him with OCD and initiated sertraline. He quickly developed agi-
tation, anxiety, and increased compulsive behaviors. The medica-
tion was discontinued and changed to risperidone. On risperidone
(dose unknown), he showed no change in symptoms and developed
weight gain and drooling. Risperidone was then changed to ar-
ipiprazole, which he was on for several months before being evalu-
ated at the university-based child/adolescent clinic.
At the university clinic evaluation, his parents reported that ar-
ipiprazole decreased his symptoms ‘‘somewhat’’ but that none-
theless the symptoms continued to cause significant distress. Given
his minimal response and a 9.1 kg weight gain, it was tapered off.
Another trial of an SSRI was agreed upon, and fluoxetine was
initially titrated to 20 mg. After 4 weeks, the patient’s symptoms
improved with regard to allowing lights to be left on at night, but
the remaining ‘‘just right’’ symptoms continued. Over the course of
6 months, fluoxetine was titrated to 100 mg, which led to a modest
decrease in symptoms. He was continued on fluoxetine, and an
incentive-based behavioral plan was initiated. This combination
decreased his symptoms by*50%. However, he continued to have
prominent symptoms of opening/shutting windows and doors,
turning lights on/off, and ordering furniture. Riluzole was added as
an augmentation agent to fluoxetine. It was titrated to 50 mg b.i.d.,
but his symptoms worsened and it was subsequently discontinued.
His fluoxetine was crossed tapered with clomipramine and titrated
up to 100 mg over the course of *2 months. It was determined,
however, that his symptoms responded better to fluoxetine, and he
was cross-tapered back to this medication. After fluoxetine was
titrated to 80 mg his OCD symptoms continued as before.
Memantine was added to augment fluoxetine. It was titrated to
15 mg and the patient’s fluoxetine was continued at 80 mg. Over the
course of 4 months, N’s symptoms significantly decreased. His
compulsive behaviors of shutting doors/windows, turning on/off
lights, and arranging items were reported to be ‘‘rare’’ by his par-
ents. However, he continued with some hoarding behaviors. His
progress was maintained over the course of 1 year.
Discussion
This case highlights the use of memantine as an augmenting
agent in a DS patient with treatment-resistant OCD. N showed
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minimal response to and/or significant side effects from first-line
SSRI agents as well as second-line strategies using atypical anti-
psychotics and a serotonin-norepinephrenine agent. An incentive-
based behavioral protocol modified for N’s developmental level
combined with a high dose of fluoxetine demonstrated modest
gains. However, it was not until N’s treatment was augmented with
memantine that any substantial improvement arose.
N’s case highlights several important issues in treating DS
patients with OCD. Diagnosing OCD in DS populations with
developmental delay is challenging, as they often do not meet
Diagnostic and Statistical Manual of Mental Disorders, 4th ed.
(DSM-IV) criteria, and their developmental delay often hinders
the use of diagnostic measures used for nondevelopmentally de-
layed patients (American Psychiatric Association 1994). Cur-
rently, there are no standard measures used to diagnosis or monitor
symptoms in developmentally delayed patients with OCD. Di-
agnosing N was based on his symptoms of compulsive behaviors
of ordering and symmetry that seemed to be driven by ‘‘just right’’
compulsions. This case, therefore, supports previous literature
speculating that OCD in DS populations often presents with re-
arranging personal belongs or opening/closing doors, cabinets,
blinds, and light switches (Prasher and Day 1995; Capone et al.
2006). Further research in the diagnosis of OCD in developmen-
tally delayed patients is warranted.
There are few studies investigating the treatment of OCD in
adult or pediatric DS patients. However, case reports have shown
that SSRIs can be effective in this population (O’Dwyer et al. 1992;
Sutor et al. 2006). Strategies for treating treatment-resistant pa-
tients with OCD and DS have emerged from treatment protocols in
nondevelopmentally disordered populations, such as augmenting
with atypical antipsychotics. Sutor et al. reported four cases of
OCD in DS patients that responded to either an SSRI alone or a
combination of an SSRI and risperidone (Sutor et al. 2006).
However, beyond this, we found no further studies investigating
treatment-resistant OCD in adult or pediatric DS populations.
Memantine is a glutamate receptor antagonist developed to slow
the development of Alzheimer’s disease (AD). In AD, memantine
is thought to decrease glutamate release by binding with a low
affinity to the N-methyl-d-aspartate (NMDA) type receptor, which
can ultimately inhibit the neurotoxic effects of prolonged calcium
influx (Choi 1992; Parsons et al. 2007). Emerging lines of evidence
have also implicated the role of glutamate dysfunction in the
pathogenesis of OCD (Wu et al. 2012). Interestingly, patients
with DS have an early onset of AD, and memantine has been
successfully used in these patients to slow cognitive decline
(Prasher 2004; Mohan, Bennett, Carpenter, 2009). Several case
reports (Poyurovsky et al. 2005; Hezel et al. 2006; Pasquini and
Biondi 2006; Aboujaoude, Barry, Gamel, 2009) as well as a recent
single-blinded case-control study (Stewart et al. 2010) have fur-
ther demonstrated memantine as an effective augmenting agent
in treatment-resistant OCD patients.
The glutamenergic theory for the pathogenesis of OCD sup-
ports the use of memantine as a novel agent (Wu et al. 2012;
Pittenger, Bloch, Williams, 2011). It is notable that memantine
has been used to slow cognitive decline in DS populations with
early-onset AD, presumably by decreasing the neurotoxic effects
of increased glutamate release, as has been stated (Prasher 2004).
Whether there is a direct correlation between AD and OCD
through a common dysfunction in the glutamate pathway remains
to be seen. Although memantine has been used to treat cognitive
decline in DS populations with AD, this is the first report that we
are aware of for its use for DS patients with OCD.
Another glutamate agent, riluzole, is also used in DS populations
with AD as well as being an emerging agent in treatment-resistant
OCD (Prahser 2004; Coric et al. 2005; Grant et al. 2007). In this
case, riluzole caused side effects, rendering it ineffective for our
patient. Why N was not able to tolerate one glutamate agent and
showed a robust response to the other is unknown. However,
memantine and riluzole are believed to have different mechanisms
of actions that may explain the differing effects. This case, there-
fore, suggests considering another glutamate agent if the first one is
not tolerated.
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